Add FDA Prizer-BioNTech release with preliminary approval of this vac…

…cine
ljl-covid · Dec 8, 2020 · 05df020 · 05df020
1 parent 5ba71b2
commit 05df020
Showing 1 changed file with 1 addition and 1 deletion.
diff --git a/README.md b/README.md
@@ -403,7 +403,7 @@ There is mixed advice on the use of masks by the general public, and the advice
 * [Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose](https://sputnikvaccine.com/newsroom/pressreleases/second-interim-analysis-of-clinical-trial-data-showed-a-91-4-efficacy-for-the-sputnik-v-vaccine-on-d/), as announced by Gamaleya in a press release, where it was also specified that no significant adverse reactions have occurred; the international price for this vaccine was stated as being below $10
 * [Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization](https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study) in a press release where efficacy is put at 94.1%, with 100% efficacy against "severe" cases, after 196 COVID cases have developed within the trial participants, and after more than two months of follow-up
 * [The Wuhan files — Leaked documents reveal China's mishandling of the early stages of Covid-19](https://edition.cnn.com/2020/11/30/asia/wuhan-china-covid-intl/index.html) is a CNN release of excerpts of private documents from the Chinese government supposedly showing cover-ups of facts about the epidemic, including a 20-fold increase of what was thought to be influenza in Hubei during December 2019
-
+* [Pfizer-BioNTech COVID-19 vaccine and related biological product advisory committee briefing document](https://www.fda.gov/media/144246/download) announces that this vaccine meets the FDA success criteria, with vaccine efficacy after the booster dose at 95.0%, counting 8 COVID-19 cases in the vaccine group compared to 162 COVID-19 cases in the placebo group, with a 95% credible interval of 90.3% to 97.6%
 
 ## API and feeds